ArticleDisease markers2016
Discovery of Novel Biomarkers for Alzheimer's Disease from Blood.
Article in Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through RNA sequencing analysis.Alzheimer's research & therapy · 2020Pooled it
- Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease.Molecular brain · 2019Pooled it
- Single-nucleus transcriptome atlas of the basal forebrain reveals diverse ageing-related pathways.Brain : a journal of neurology · 2025Article
- Machine-learning based strategy identifies a robust protein biomarker panel for Alzheimer's disease in cerebrospinal fluid.Alzheimer's research & therapy · 2025Article
- Comparison of Deep Learning and Traditional Machine Learning Models for Predicting Mild Cognitive Impairment Using Plasma Proteomic Biomarkers.International journal of molecular sciences · 2025Article
- Improving machine learning detection of Alzheimer disease using enhanced manta ray gene selection of Alzheimer gene expression datasets.PeerJ. Computer science · 2025Article
- Cladribine tablets in the new multiple sclerosis era.Therapeutic advances in neurological disorders · 2025Review
- The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics.CNS neuroscience & therapeutics · 2024Review
- Elucidation of the effects of 2,5-hexandione as a metabolite ofToxicological research · 2024Article
- Enoyl coenzyme a hydratase 1 attenuates aortic valve calcification by suppressing Runx2 via Wnt5a/CaJournal of cell communication and signaling · 2024Article
- DYT-THAP1: exploring gene expression in fibroblasts for potential biomarker discovery.Neurogenetics · 2024Article
- Blood biomarker-based classification study for neurodegenerative diseases.Scientific reports · 2023Article
- Molecular signature associated with cladribine treatment in patients with multiple sclerosis.Frontiers in immunology · 2023Article
- Bioinformatics Analysis IdentifiesDisease markers · 2023Article
- Novel patients with NHLRC2 variants expand the phenotypic spectrum of FINCA disease.Frontiers in neuroscience · 2023Article
- Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through immune landscape analysis.npj aging · 2022Article
- Dietary Selenomethionine Reduce Mercury Tissue Levels and Modulate Methylmercury Induced Proteomic and Transcriptomic Alterations in Hippocampi of Adolescent BALB/c Mice.International journal of molecular sciences · 2022Article
- Structure of Arabidopsis SOQ1 lumenal region unveils C-terminal domain essential for negative regulation of photoprotective qH.Nature plants · 2022Article
- Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.Metabolic brain disease · 2022Review
- Machine Learning Models to Predict Cognitive Impairment of Rodents Subjected to Space Radiation.Frontiers in systems neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood-based biomarkers for Alzheimer's disease would be very valuable because blood is a more accessible biofluid and is suitable for repeated sampling. However, currently there are no robust and reliable blood-based biomarkers for practical diagnosis. In this study we used a knowledge-based protein feature pool and two novel support vector machine embedded feature selection methods to find panels consisting of two and three biomarkers. We validated these biomarker sets using another serum cohort and an RNA profile cohort from the brain. Our panels included the proteins ECH1, NHLRC2, HOXB7, FN1, ERBB2, and SLC6A13 and demonstrated promising sensitivity (>87%), specificity (>91%), and accuracy (>89%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.